Variant: rs17851045 

    present in Gene: KRAS
    present in Chromosome: 12
    Position on Chromosome: 25227341
    Alleles of this Variant: T/A;G

rs17851045 in KRAS gene and Adenocarcinoma of lung (disorder) PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs17851045 in KRAS gene and Adenocarcinoma of pancreas PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs17851045 in KRAS gene and Chronic Lymphocytic Leukemia PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs17851045 in KRAS gene and Colorectal Neoplasms PMID 20921462 2010 Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

PMID 20921465 2010 Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

PMID 22722830 2012 Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

PMID 16618717 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

PMID 18316791 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

PMID 19679400 2009 Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.

PMID 19114683 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

PMID 16361624 2005 Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.

PMID 21228335 2011 Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 23325582 2013 Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs17851045 in KRAS gene and Cutaneous Melanoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs17851045 in KRAS gene and Gastric Adenocarcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs17851045 in KRAS gene and Leukemia, Myelocytic, Acute PMID 19075190 2009 High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

PMID 2278970 1990 RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study.

PMID 3122217 1987 RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

PMID 16434492 2006 Implications of NRAS mutations in AML: a study of 2502 patients.

PMID 22407852 2012 RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs17851045 in KRAS gene and Liver carcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs17851045 in KRAS gene and Malignant Uterine Corpus Neoplasm PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs17851045 in KRAS gene and Multiple Myeloma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs17851045 in KRAS gene and Non-Small Cell Lung Carcinoma PMID 18794081 2008 Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

PMID 15696205 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

PMID 12460918 2002 BRAF and RAS mutations in human lung cancer and melanoma.

rs17851045 in KRAS gene and Squamous cell carcinoma of lung PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs17851045 in KRAS gene and Thyroid Neoplasm PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs17851045 in KRAS gene and Transitional cell carcinoma of bladder PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.